Phio Pharmaceuticals Corp. will participate in Renmark Financial Communications’ live Virtual Non-Deal Roadshow Series with a live presentation and Q&A on Monday, March 9, 2026 at 10:00 a.m. EDT, where CEO Robert Bitterman will discuss the INTASYL siRNA platform and PH-762 Phase 1b results. Event registration: https://api.newsfilecorp.com/redirect/5WegJuWzkk. Replay access: https://www.renmarkfinancial.com/vndrs. Source press release: https://www.newsfilecorp.com/release/286314.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.
Comments